<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Cancer Detection | Ioannis Mouratidis</title><link>https://ioannis-mouratidis.github.io/tags/Cancer-Detection/</link><atom:link href="https://ioannis-mouratidis.github.io/tags/Cancer-Detection/index.xml" rel="self" type="application/rss+xml"/><description>Cancer Detection</description><generator>Hugo Blox Builder (https://hugoblox.com)</generator><language>en-us</language><lastBuildDate>Mon, 01 Dec 2025 00:00:00 +0000</lastBuildDate><image><url>https://ioannis-mouratidis.github.io/media/icon_hu_899445b689d8f445.png</url><title>Cancer Detection</title><link>https://ioannis-mouratidis.github.io/tags/Cancer-Detection/</link></image><item><title>Leveraging sequences missing from the human genome to diagnose cancer</title><link>https://ioannis-mouratidis.github.io/talks/cmc-symposium-2025/</link><pubDate>Mon, 01 Dec 2025 00:00:00 +0000</pubDate><guid>https://ioannis-mouratidis.github.io/talks/cmc-symposium-2025/</guid><description>&lt;p&gt;Oral presentation on leveraging sequences absent from the human genome for cancer diagnosis.&lt;/p&gt;</description></item><item><title>Leveraging sequences missing from the human genome to diagnose cancer</title><link>https://ioannis-mouratidis.github.io/publications/cancer-detection-2025/</link><pubDate>Wed, 01 Jan 2025 00:00:00 +0000</pubDate><guid>https://ioannis-mouratidis.github.io/publications/cancer-detection-2025/</guid><description>&lt;p&gt;This work demonstrates how sequences that are absent from the human genome can be leveraged as biomarkers for cancer detection, with potential applications in liquid biopsy-based diagnostics.&lt;/p&gt;</description></item><item><title>Leveraging sequences missing from the human genome to diagnose cancer</title><link>https://ioannis-mouratidis.github.io/talks/beat-cancer-2024/</link><pubDate>Thu, 01 Feb 2024 00:00:00 +0000</pubDate><guid>https://ioannis-mouratidis.github.io/talks/beat-cancer-2024/</guid><description>&lt;p&gt;Invited talk on leveraging nullomers for cancer diagnosis. Presented at the Beat Childhood Cancer Research Consortium Annual Meeting with approximately 150 attendees.&lt;/p&gt;</description></item><item><title>Leveraging sequences missing from the human genome to diagnose cancer</title><link>https://ioannis-mouratidis.github.io/talks/cancer-research-day-2023/</link><pubDate>Sun, 01 Oct 2023 00:00:00 +0000</pubDate><guid>https://ioannis-mouratidis.github.io/talks/cancer-research-day-2023/</guid><description>&lt;p&gt;Oral presentation on leveraging sequences absent from the human genome for cancer diagnosis. Presented at Cancer Research Day with approximately 150 attendees.&lt;/p&gt;</description></item><item><title>Neomer Diagnostics</title><link>https://ioannis-mouratidis.github.io/projects/neomer-diagnostics/</link><pubDate>Sat, 01 Jan 2022 00:00:00 +0000</pubDate><guid>https://ioannis-mouratidis.github.io/projects/neomer-diagnostics/</guid><description>&lt;h2 id="overview"&gt;Overview&lt;/h2&gt;
&lt;p&gt;Co-founded Neomer Diagnostics in 2022 as Chief Technical Officer to translate patented nullomer research into a clinical cancer detection platform. The company developed machine learning pipelines for detecting cancer from liquid biopsies.&lt;/p&gt;
&lt;h2 id="role--achievements"&gt;Role &amp;amp; Achievements&lt;/h2&gt;
&lt;p&gt;As CTO, I:&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;Developed ML pipeline in Bash, Julia, Python, and Slurm for cancer detection from liquid biopsies&lt;/li&gt;
&lt;li&gt;Achieved AUC ranging from 0.89 to 0.94 in lung and ovarian cancers&lt;/li&gt;
&lt;li&gt;Established regulatory roadmap for clinical validation and FDA approval&lt;/li&gt;
&lt;li&gt;Secured $850K in translational research funding&lt;/li&gt;
&lt;li&gt;Led technical team and coordinated with clinical partners&lt;/li&gt;
&lt;/ul&gt;
&lt;h2 id="technology"&gt;Technology&lt;/h2&gt;
&lt;p&gt;The platform leveraged sequences absent from the human genome (nullomers) as biomarkers for cancer detection. Machine learning models were trained on cell-free DNA and RNA data from liquid biopsies to distinguish cancer patients from healthy controls.&lt;/p&gt;
&lt;h2 id="clinical-applications"&gt;Clinical Applications&lt;/h2&gt;
&lt;ul&gt;
&lt;li&gt;Early cancer detection&lt;/li&gt;
&lt;li&gt;Cancer screening in high-risk populations&lt;/li&gt;
&lt;li&gt;Monitoring treatment response&lt;/li&gt;
&lt;li&gt;Detecting minimal residual disease&lt;/li&gt;
&lt;/ul&gt;
&lt;h2 id="funding--recognition"&gt;Funding &amp;amp; Recognition&lt;/h2&gt;
&lt;ul&gt;
&lt;li&gt;Secured $850K in translational research funding&lt;/li&gt;
&lt;li&gt;Patent portfolio covering nullomer-based diagnostics&lt;/li&gt;
&lt;li&gt;Partnerships with clinical institutions&lt;/li&gt;
&lt;/ul&gt;
&lt;h2 id="period"&gt;Period&lt;/h2&gt;
&lt;p&gt;January 2022 - May 2023&lt;/p&gt;</description></item></channel></rss>